Page 6 of 8: studies 101 to 120 of 151, newest first. Back to the serotonin overview
Journal of Medicinal Chemistry May 1, 2025 Saghir Ali, Xiaochen Tian, Kathryn A. Cunningham et al. 5 citations
Targeting the 5-HT2A Receptor for Developing Psychedelic Drugs and Beyond.
Cephalalgia Reports May 1, 2025 Jonathan A. Leighton, Chieh Grace Lau, Aisha Savdo et al. 2 citations
Background Cluster headache is an excruciating condition for which standard treatments are usually insufficient. Evidence has accumulated that serotonergic psychedelic indoleamines including psilocybin and LSD can be effective in preventing attacks. Methods In this case series, nine patients with episodic and chronic cluster headache that didn’t respond to conventional treatments were treated...
Pharmacological Research May 1, 2025 Eda Koseli, Belle Buzzi, Torin Honaker et al. 11 citations
Chronic pain is a debilitating disease with current treatments lacking efficacy and safety, therefore discovery of new treatments is crucial. Initial studies suggest that psychedelics may be feasible for targeting pain, however clinical and preclinical controlled studies are necessary to further investigate that possibility. In this study we assessed the effects of two classical psychedelics...
Neurobiology of Stress May 1, 2025 Alanna Kit, Kate Conway, Savannah Makarowski et al. 5 citations
There is growing interest in exploring the therapeutic potential and mechanisms of action of psilocybin on stress-related neuropsychiatric disorders, including depression, generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), addiction, and disordered eating. Despite promising progressions in preclinical and clinical research, the...
Pharmacological Reviews April 23, 2025 Benjamin R. Cummins, Gerald Billac, David E Nichols et al. 62 citations
Serotonin 5-HT2A receptors were one of the first serotonin receptors to be pharmacologically characterized. In mammals, they are expressed throughout the body in nearly every cell and tissue type, with the highest density in cortical layer V of the brain. They are involved in several aspects of normal physiological processes and behaviors and have been implicated in the etiology of...
Neuropsychopharmacology April 22, 2025 Briana K Chen, Alicia Whye, Louise C Matthews et al. 2 citations
Serotonin (5-HT) receptors and N-methyl-D-aspartate receptors (NMDARs) have both been implicated in stress-induced psychiatric disorders. However, there is a paucity of studies evaluating the effectiveness of novel combinatorial pharmacological treatments to treat stress-related disorders. Here, we evaluated whether administration of combinatorial (R,S)-ketamine, an NMDAR antagonist and Food...
Psychopharmacology April 21, 2025 Noah N T Barr, Kayla J Giese, Sam G. Moreton 1 citation
Emerging evidence suggests that psychedelic experiences have the potential to change attitudes towards death and reduce death anxiety. Improved attitudes towards death, specifically reduced death anxiety, are of psychological significance for clinical and non-clinical populations alike. Despite this emerging evidence, little is known about the phenomenology of this potential outcome. To provide...
Communications Biology April 18, 2025 S Parker Singleton, Christopher Timmermann, Andrea I. Luppi et al. 17 citations
Psychedelics offer a profound window into the human brain through their robust effects on perception, subjective experience, and brain activity patterns. The serotonergic psychedelic N,N-dimethyltryptamine (DMT) induces a profoundly immersive altered state of consciousness lasting under 20 min, allowing the entire experience to be captured during a single functional magnetic resonance imaging...
Schizophrenia Bulletin April 17, 2025 Nathan H. Heller, Frederick S. Barrett, Tobias Buchborn et al. 3 citations
Abstract Background and Hypothesis Visual hallucinations (VH) are a core symptom of both Lewy body diseases (LBDs; eg, Parkinson’s disease and dementia with Lewy bodies) and serotonergic psychedelics (SPs; eg, psilocybin and mescaline). While these conditions differ in etiology, overlapping phenomenology, and neural mechanisms suggest shared pathways. This review explores similarities and...
Journal of Psychopharmacology April 17, 2025 Artur Pałasz, Marta Pukowiec, Katarzyna Bogus et al.
Objective: Psychedelics are able to trigger highly intense and profound alterations in self-consciousness, perception, affective, and cognitive processes. Indeed, recent studies show that ketamine and psilocybin could be used as fast-acting antidepressants. However, the molecular and neurochemical mechanisms of these psychedelics and their actions at the level of diverse brain structures...
Renal Replacement Therapy April 15, 2025 Kazuhiro Okamoto, Nobuhiro Hashimoto, Kaiya Ishizeki et al.
Dextromethorphan (DXM) misuse, particularly among young individuals, has risen owing to its euphoric and hallucinogenic effects. High-dose DXM ingestion can trigger serotonin syndrome, a condition characterized by psychiatric, neuromuscular, and autonomic symptoms. In severe cases, serotonin syndrome may result in rhabdomyolysis and acute kidney injury (AKI). However, reports of severe...
Naunyn-Schmiedeberg's Archives of Pharmacology April 15, 2025 Arya Afrooghe, Elham Ahmadi, Ali Lesani et al.
We aimed to investigate whether psilocin, the bioactive metabolite of the well-known psychedelic, psilocybin, may have antipruritic effects in mice by interfering with the kynurenine pathway and interacting with 5-HT2A receptors. Eight mice were randomly assigned to each of the study groups receiving either normal saline, compound 48/80, psilocin (0.3, 1, and 3 mg/kg), or psilocin (1 mg/kg) +...
Journal of Psychopharmacology April 4, 2025 Rebecca D. Hill, Ritu A. Shetty, Nathalie Sumien et al.
New synthetic tryptamine derivatives have emerged in the underground market. They act on serotonin receptors mimicking the effects of hallucinogenic drugs such as DOM. The DEA has identified three tryptamine derivatives of concern, 5-MeO-DBT, 5-Cl-DMT, and 4-OH-MiPT. Swiss Webster mice were tested for locomotor activity. Discriminative stimulus effects were tested in male Sprague-Dawley rats...
International Journal of Science and Research (IJSR) April 3, 2025 David Nisenboim
Medical treatment for behavioral disorders such as anxiety, depression, and post-traumatic stress disorder (PTSD) represent emerging challenges in the field and have been a subject of studies for a long time. Available therapeutics include selective serotonin reuptake inhibitors (SSRIs), Monoamine oxidase inhibitors (MAOIs), tricyclics, etc. Nevertheless, recent studies have identified a...
International Journal of Mental Health and Addiction April 1, 2025 Joshua C. Black, Nicole Schow, Hannah L. Burkett et al. 3 citations
Psychedelic-assisted therapy could transform treating psychiatric illness, but harms from exacerbating substance use disorder (SUD) among adults with psychiatric illness using psychedelics have not been studied. A cross-sectional survey in the US was used to test whether Drug Abuse Screening Test scores (DAST-10, validated instrument predicting SUD) were more severe when psychiatric illnesses...
Journal of Psychopharmacology March 31, 2025 Tomislav Majić, Timo Torsten Schmidt, Anna Gröticke et al. 4 citations
Background: Classic psychedelics such as psilocybin and lysergic acid diethylamide are anecdotally associated with the phenomenon of “psychedelic afterglow,” a set of predominantly pleasant, temporary psychological effects reported after the acute effects have subsided. Since post-acute effects are crucial for the therapeutic use of psychedelics, an instrument to systematically assess subacute...
Progress in Neuro-Psychopharmacology and Biological Psychiatry March 20, 2025 Zhen Xuen Brandon Low, Shin Jie Yong, Hayam A Alrasheed et al.
In our ongoing battle against the coronavirus 2019 (COVID-19) pandemic, a major challenge is the enduring symptoms that continue after acute infection. Also known as Long COVID, post-COVID-19 syndrome (PCS) often comes with debilitating symptoms like fatigue, disordered sleep, olfactory dysfunction, and cognitive issues ("brain fog"). Currently, there are no approved treatments for PCS. Recent...
European Journal of Pharmacology March 15, 2025 James J Gattuso, Carey Wilson, Shanshan Li et al. 16 citations
Psilocybin is a serotonergic psychedelic with therapeutic potential for several neuropsychiatric disorders, including depression and anxiety disorders. Serotonin transporter (5-HTT) knockout mice (KO) are a well-validated mouse model of anxiety/depression and are relevant to both chronic treatment with serotonin transporter reuptake inhibitors (SSRIs) and polymorphisms in the serotonin...
ACS Medicinal Chemistry Letters March 13, 2025 Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel compounds as 5-HT2A receptor modulators, pharmaceutical compositions, use of such compounds in treating psychiatric and neurological disorders and processes for preparing such compounds.
Archiv der Pharmazie March 1, 2025 Giuseppe Floresta, Alberto Granzotto, Vincenzo Patamia et al. 12 citations
Abstract Xylazine, traditionally used as a veterinary sedative, has recently emerged as a new psychoactive substance, being typically ingested in combination with fentanyl derivatives and hence raising significant public health concerns. Despite its increasing prevalence, little is known about its molecular interactions with human neuroreceptors, specifically the serotonin 7 (5‐HT 7 R) and...